<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02345057</url>
  </required_header>
  <id_info>
    <org_study_id>CS3150-B-J204</org_study_id>
    <nct_id>NCT02345057</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Type 2 Diabetic Subjects With Microalbuminuria</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Subjects With Type 2 Diabetes Mellitus and Microalbuminuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, placebo-controlled, double-blind, multi-center study to evaluate
      efficacy and safety of different doses of CS-3150 compared to placebo in Japanese Type 2
      Diabetes Mellitus and Microalbuminuria.

      The Primary endpoint is the change from baseline in urinary albumin to creatine ratio (UACR).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in urinary albumin to creatine ratio (UACR)</measure>
    <time_frame>Baseline to end of Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transition from microalbuminuria to normoalbuminuria</measure>
    <time_frame>Baseline to end of Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in renal function</measure>
    <time_frame>Baseline to end of Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum potassium</measure>
    <time_frame>Baseline to end of Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">365</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>CS-3150 0.625 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One CS-3150 0.625 mg tablet and one placebo tablet to match CS-3150 tablet administered orally, once daily after breakfast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CS-3150 1.25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two CS-3150 0.625 mg tablets administered orally, once daily after breakfast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CS-3150 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One CS-3150 2.5 mg tablet and one placebo tablet to match CS-3150 tablet administered orally, once daily after breakfast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CS-3150 5.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two CS-3150 2.5 mg tablets administered orally, once daily after breakfast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two placebo tablets to match CS-3150 tablet, administered orally, once daily after breakfast.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS-3150</intervention_name>
    <arm_group_label>CS-3150 0.625 mg</arm_group_label>
    <arm_group_label>CS-3150 1.25 mg</arm_group_label>
    <arm_group_label>CS-3150 2.5 mg</arm_group_label>
    <arm_group_label>CS-3150 5.0 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>CS-3150 0.625 mg</arm_group_label>
    <arm_group_label>CS-3150 2.5 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with type 2 diabetes mellitus

          -  Male or female subjects aged 20 years or older at informed consent

          -  Subjects with urinary albumin to creatine ratio (UACR) ≥ 45 mg/g Cr and &lt; 300 mg/g Cr

          -  Estimated glomerular filtration rate by creatinine (eGFRcreat) ≥ 30 mL/min/1.73 m^2

          -  Subjects treated with angiotensin-converting enzyme inhibitor (ACEi) or angiotensin
             receptor blocker (ARB) for at least 3 months prior to treatment period

        Exclusion Criteria:

          -  Type 1 diabetes

          -  HbA1c (NGSP) &gt;=8.4%

          -  Secondary glucose intolerance

          -  Subjects diagnosed with non-diabetic nephropathy

          -  Nephrotic syndrome

          -  Secondary hypertension or malignant hypertension

          -  Serum potassium level in any of the following categories: For subjects with eGFRcreat
             of ≥ 45 mL/min/1.73 m^2, serum potassium level of &lt; 3.5 mEq/L or ≥ 5.1 mEq/L; For
             subjects with eGFRcreat of ≥ 30 mL/min/1.73 m^2 and &lt; 45 mL/min/1.73 m^2, serum
             potassium level of &lt; 3.5 mEq/L or ≥ 4.8 mEq/L
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Kumamoto</city>
        <zip>862-0976</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>January 19, 2015</study_first_submitted>
  <study_first_submitted_qc>January 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <last_update_submitted>December 19, 2018</last_update_submitted>
  <last_update_submitted_qc>December 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Nephropathy</keyword>
  <keyword>mineralocorticoid receptor antagonist</keyword>
  <keyword>CS-3150</keyword>
  <keyword>Japanese</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/daiichi-sankyo/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

